Danavorexton - Takeda
Alternative Names: TAK-925Latest Information Update: 07 Jul 2025
At a glance
- Originator Takeda
- Class Cyclohexanes; Esters; Ethers; Piperidines; Sleep disorder therapies; Small molecules; Sulfonamides
- Mechanism of Action Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Idiopathic hypersomnia; Narcolepsy; Neurological disorders; Respiration disorders; Sleep apnoea syndrome
Most Recent Events
- 07 Jul 2025 Discontinued - Phase-I for Idiopathic hypersomnia (In the elderly, In adults) in USA, Japan (IV) (Takeda pipeline, July 2025)
- 07 Jul 2025 Discontinued - Phase-I for Narcolepsy (In the elderly, In adults) in Japan (IV) (Takeda pipeline, July 2025)
- 07 Jul 2025 Discontinued - Phase-I for Narcolepsy (In volunteers) in USA (IV) (Takeda pipeline, July 2025)